CRTX Insider Trading
Insider Ownership Percentage: 27.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Cortexyme Share Price & Price History
Current Price: $1.32
Price Change: ▲ Price Increase of +0.05 (3.94%)
As of 04/2/2025 01:00 AM ET
Cortexyme Insider Trading History
Cortexyme Institutional Trading History
Data available starting January 2016
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More on Cortexyme
Volume
38,362 shs
Average Volume
620,672 shs
Market Capitalization
$39.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.4